In 2025, the total compensation amount for innovative medical devices in commercial health insurance reached 14.7 billion yuan, with a compound annual growth rate of 70%.

The Insurance Association convened a seminar on the high-quality development of health insurance in Beijing today, where representatives pointed out that in recent years, commercial health insurance has continuously expanded coverage and enhanced health protection service capabilities. Ten years ago, CAR-T drugs costing over one million yuan were already included in the list of responsibilities. Currently, most mainstream medical insurance products in the market include coverage for new technologies, new drugs, and new equipment, covering high-value technologies such as targeted cancer drugs and proton therapy. Preliminary estimates suggest that by 2025, the total payout for innovative drugs and equipment under commercial health insurance will be approximately 14.7 billion yuan, with a high-speed growth for four consecutive years, and a compound annual growth rate of 70%.